- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03546322
Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The investigators aim to implement and evaluate a health information technology (HIT) registry at an urban, public delivery system. The investigators will not assign specific interventions to the study participants, but rather observationally assess the effect of the HIT registry, designed to support routine medical care, on participants.
The investigators will use systems engineering methodologies to design, develop, and implement the platform. The platform will be implemented in the Otolaryngology - Head and Neck Surgery clinic that cares for patients with head and neck cancers. The study will assess patient outcomes and evaluate the time it takes for patients to progress through key treatment and post-treatment milestones before and after the HIT tool is implemented. The investigators will use models controlling for secular trend to estimate the effect of the tool on improving timely and successful completion of guideline-based care processes.
The HIT platform seeks to improve the monitoring and alerting functionality of existing systems. Specifically, it replaces paper-based systems previously used by the clinic to monitor its head and neck cancer patients. It will be implemented clinic-wide for all patients being treated for head and neck cancers. The investigators are not assigning a specific intervention to patients, but rather supporting the clinic and health system in the development of a population management platform that improves routine care processes. The platform is approved for clinical use and research by the San Francisco Health Network and the University of California, San Francisco.
The HIT platform users are clinicians who are responsible for monitoring patients with head and neck cancer and agree to partner with the investigators to improve monitoring processes. The clinicians involved may be asked to voluntarily participate in surveys, interviews, focus groups, and program evaluations. Patient medical records will be reviewed, but patients monitored on the registry will not be contacted by researchers.
Procedures are in place to monitor the registry. First, quality assurance is performed by the research team, information technology analysts, and software engineers. This includes checking that data in the platform matches source data, such as data entered in the electronic health record. In addition, the platform users are audited on a weekly basis. A data dictionary defining variables used in the platform exists and is updated as needed. Patients will be added to the registry by a clinician if they are diagnosed with head and neck cancer. The research team will support the clinicians in data analysis, although this will be performed with population-level, de-identified data. However, if unmediated adverse events are identified by the research team, the research team will alert the clinicians immediately. The HIT platform is designed to supplement, but not replace, the existing electronic health record. Data on the registry will be validated with source data and users will still engage with the source data and electronic health record as appropriate clinically and operationally.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94110
- Zuckerberg San Francisco General Hospital and Trauma Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Patients with head and neck surgery monitored by the Otolaryngology - Head and Neck Surgery Clinic
Exclusion Criteria:
- N/A
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Registry
Head and neck cancer patients monitored on registry
|
Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group.
The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients.
All head and neck cancer patients monitored by the clinic will be included.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Workup and Treatment Planning - Primary Outcome
Délai: From date of diagnosis to first date of treatment, assessed up to 5 years
|
Time from diagnosis to initiation of treatment
|
From date of diagnosis to first date of treatment, assessed up to 5 years
|
Treatment - Primary Outcome
Délai: 5 years
|
Proportion of patients that complete tumor board treatment recommendations
|
5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Workup and Treatment Planning - Secondary Outcome #1
Délai: From date of diagnosis to presentation at tumor board, assessed up to 5 years
|
Time from diagnosis to presentation at tumor board
|
From date of diagnosis to presentation at tumor board, assessed up to 5 years
|
Workup and Treatment Planning - Secondary Outcome #2
Délai: From date of diagnosis to date of dental evaluation for patients undergoing radiation treatment, assessed up to 5 years
|
Time from diagnosis to dental evaluation
|
From date of diagnosis to date of dental evaluation for patients undergoing radiation treatment, assessed up to 5 years
|
Workup and Treatment Planning - Secondary Outcome #3
Délai: From date of diagnosis to date of first visit with oncology clinic, assessed up to 5 years
|
Time from diagnosis to first visit in oncology clinics
|
From date of diagnosis to date of first visit with oncology clinic, assessed up to 5 years
|
Treatment - Secondary Outcome
Délai: 6 weeks
|
Proportion of patients who complete post-treatment radiation
|
6 weeks
|
Loss to follow-up
Délai: 5 years
|
Proportion of patients who are lost to follow-up
|
5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Urmimala Sarkar, MD, MPH, University of California, San Francisco
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P30HS023558-1
- P30HS023558 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs de la tête et du cou
-
Mathematica Policy Research, Inc.Boston Children's Hospital; Department of Health and Human ServicesPas encore de recrutementIntervention précoce, éducation (Head Start et Early Head Start Access and Participation)États-Unis
-
Novartis PharmaceuticalsActif, ne recrute pasAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MélanomeTaïwan, États-Unis, Pays-Bas, Espagne, Corée, République de, Italie, Japon, Canada, Singapour
Essais cliniques sur Registry
-
Kaohsiung Medical University Chung-Ho Memorial...ComplétéCarcinome hépatocellulaire | Métastase | InvasionTaïwan